abrdn plc boosted its holdings in Xylem Inc. (NYSE:XYL - Free Report) by 2.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,083,405 shares of the industrial products company's stock after purchasing an additional 23,736 shares during the quarter. abrdn plc owned about 0.45% of Xylem worth $145,030,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in the business. City Holding Co. increased its holdings in Xylem by 3.8% in the third quarter. City Holding Co. now owns 2,071 shares of the industrial products company's stock worth $280,000 after purchasing an additional 75 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Xylem by 68.8% during the first quarter. EverSource Wealth Advisors LLC now owns 189 shares of the industrial products company's stock valued at $25,000 after acquiring an additional 77 shares in the last quarter. Whittier Trust Co. of Nevada Inc. increased its holdings in shares of Xylem by 3.5% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 2,317 shares of the industrial products company's stock valued at $299,000 after acquiring an additional 79 shares in the last quarter. Addison Advisors LLC increased its holdings in shares of Xylem by 5.8% during the second quarter. Addison Advisors LLC now owns 1,486 shares of the industrial products company's stock valued at $202,000 after acquiring an additional 82 shares in the last quarter. Finally, Bangor Savings Bank increased its holdings in shares of Xylem by 56.7% during the third quarter. Bangor Savings Bank now owns 235 shares of the industrial products company's stock valued at $32,000 after acquiring an additional 85 shares in the last quarter. 87.96% of the stock is currently owned by institutional investors.
Xylem Stock Performance
XYL stock traded down $0.90 during midday trading on Tuesday, hitting $129.89. The company's stock had a trading volume of 939,539 shares, compared to its average volume of 1,176,563. The stock's 50-day moving average price is $133.60 and its 200 day moving average price is $135.30. The company has a quick ratio of 1.33, a current ratio of 1.85 and a debt-to-equity ratio of 0.19. Xylem Inc. has a 1 year low of $87.59 and a 1 year high of $146.08. The stock has a market cap of $31.55 billion, a price-to-earnings ratio of 41.40, a PEG ratio of 2.30 and a beta of 1.04.
Xylem (NYSE:XYL - Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The industrial products company reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.04. Xylem had a return on equity of 9.48% and a net margin of 9.11%. The business had revenue of $2.17 billion for the quarter, compared to analysts' expectations of $2.14 billion. During the same quarter in the previous year, the firm earned $0.98 earnings per share. The business's revenue was up 26.0% on a year-over-year basis. On average, equities analysts forecast that Xylem Inc. will post 4.26 EPS for the current year.
Xylem Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 26th. Shareholders of record on Thursday, August 29th were given a $0.36 dividend. The ex-dividend date was Thursday, August 29th. This represents a $1.44 annualized dividend and a yield of 1.11%. Xylem's dividend payout ratio is currently 45.57%.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on the company. TD Cowen restated a "hold" rating and set a $138.00 price objective on shares of Xylem in a report on Tuesday, September 3rd. Royal Bank of Canada boosted their price objective on Xylem from $160.00 to $163.00 and gave the company an "outperform" rating in a report on Wednesday, July 31st. Robert W. Baird lifted their target price on Xylem from $155.00 to $170.00 and gave the company an "outperform" rating in a research report on Wednesday, July 31st. Stifel Nicolaus lifted their target price on Xylem from $170.00 to $172.00 and gave the company a "buy" rating in a research report on Wednesday, July 31st. Finally, UBS Group assumed coverage on Xylem in a research report on Tuesday, August 13th. They set a "buy" rating and a $165.00 target price on the stock. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $149.67.
Get Our Latest Research Report on Xylem
Xylem Profile
(
Free Report)
Xylem Inc, together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions worldwide. It operates through four segments: Water Infrastructure, Applied Water, Measurement & Control Solutions, and Integrated Solutions and Services. The Water Infrastructure segment offers products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the ADI, Flygt, Godwin, Sanitaire, Magneto, Neptune Benson, Ionpure, Leopold, Wedeco, and Xylem Vue brands.
Read More
Before you consider Xylem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xylem wasn't on the list.
While Xylem currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.